Clinical trial Recruiting at 1 site Observational Ages 18 and up

Measuring brain-surface iron with MRI in superficial siderosis

Official title: Haemdall: Developing a Quantitative MRI Biomarker of Classical (Infratentorial) Superficial Siderosis of the Central Nervous System

Run by Perspectum · NCT07098650 · Data updated 2026-11-12

This project will try a new MRI technique to measure iron on the surface of the brain in adults with superficial siderosis and compare findings to healthy adults.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment50 (estimated)
SponsorPerspectum
Industry-sponsored
Locations1 site (Oxford)
StatusRecruiting
StartedAugust 14, 2025
Main results expectedOctober 31, 2026
Study endsDecember 31, 2026
Registry record updatedAugust 20, 2025
Trial IDNCT07098650 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal participants are adults (18+) with a confirmed diagnosis of superficial siderosis who can consent and communicate in English, or healthy adults without neurological disorders to serve as controls.

Probably not a fit

People under 18, those without a confirmed diagnosis, individuals who cannot undergo MRI due to incompatible implants or severe claustrophobia, or those unable to give informed consent are unlikely to benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational project uses quantitative susceptibility mapping (QSM), an MRI method, to quantify iron accumulation on the brain surface in people with infratentorial superficial siderosis and in healthy control participants. Participants will have specialized MRI scans and a battery of clinical tests including hearing evaluations, walking and balance assessments, and cognitive testing. Researchers will compare the MRI-derived iron measurements with symptom severity to see if imaging signals relate to clinical features. All imaging and clinical assessments are conducted on-site at Perspectum in Oxford and are noninvasive apart from standard MRI safety considerations.

Why it matters

Potential benefit: If successful, the technique could provide a noninvasive MRI biomarker to track iron burden and help monitor disease progression or responses to future treatments.

How similar studies have gone: Quantitative susceptibility mapping has been used successfully to map brain iron in disorders such as Parkinson's disease and multiple sclerosis, but applying QSM specifically to infratentorial superficial siderosis is relatively novel and not yet widely validated.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Superficial siderosis cohort:

* Male or female adults of 18 years of age or older with a confirmed diagnosis of superficial siderosis
* Participants who have the capacity and a level of English proficiency that allows him/her to communicate well with the Investigator, understand and comply with the requirements of the investigation, read all participant facing documentation, as well as read and sign the informed consent form.
* Participants willing and able to give informed consent for participation in the investigation

Healthy cohort:

* Male or female over 18 years of age without a diagnosis of a neurological disorder
* Participants who have the capacity and a level of English proficiency that allows him/her to communicate well with the Investigator, understand and comply with the requirements of the investigation, read all participant facing documentation, as well as read and sign the informed consent form.
* Participants willing and able to give informed consent for participation in the investigation

Exclusion Criteria:

* The participant may not enter the investigation if they have any contraindication to magnetic resonance imaging (including pregnancy, extensive tattoos, pacemaker, shrapnel injury or metallic unfixed implanted devices, metallic fragments, severe claustrophobia and cochlear implants)
* Any other cause, including a significant disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the investigation, or may influence the result of the investigation, or the participant's ability to participate in the investigation
* Participants who do not demonstrate the capacity to understand the investigation information or provide informed consent

Where it's running

  • Perspectum
    Oxford, United Kingdom
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Browse more
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.